Uncategorized
Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
LEXINGTON, Mass.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24ALDX&src=ctag" target="_blank">$ALDX</a>--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced quarter ended June 30, 2019 financial results and provided a corporate update. “With Part 1 of our first Phase 3 trial in dry eye disease expected to be completed later this year, Aldeyra continues to advance reproxalap, the lead product c